Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease.

被引：0
|
作者：
Straus, DJ [1 ]
Yahalom, J [1 ]
Zelenetz, AD [1 ]
Qin, J [1 ]
Myers, J [1 ]
Moskowitz, CH [1 ]
Noy, A [1 ]
Bertino, JR [1 ]
Portlock, CS [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3201
引用
收藏
页码：769A / 769A
页数：1
相关论文
共 50 条
  • [1] Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    Straus, DJ
    Portlock, CS
    Qin, J
    Myers, J
    Zelenetz, AD
    Moskowitz, C
    Noy, A
    Goy, A
    Yahalom, J
    BLOOD, 2004, 104 (12) : 3483 - 3489
  • [2] Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease
    Drings, P
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (11) : 747 - 748
  • [3] Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
    Lipton, JH
    Gospodarowicz, M
    Reingold, S
    HEMATOLOGICAL ONCOLOGY, 1996, 14 (01) : 29 - 31
  • [4] Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease:: 10-year results of a randomized trial
    le Maignan, C
    Desablens, B
    Delwail, V
    Dib, M
    Berthou, C
    Vigier, M
    Ghandour, C
    Atmani, S
    Casassus, P
    Maisonneuve, H
    Le Mevel, A
    Traullé, C
    Bernard, M
    Brière, J
    Colonna, P
    Andrieu, JM
    BLOOD, 2004, 103 (01) : 58 - 66
  • [5] Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor
    Gastaldi, R
    Martino, P
    Gentile, G
    Picardi, V
    De Propris, MS
    Pirillo, MF
    De Vellis, A
    Mandelli, F
    ANNALS OF ONCOLOGY, 2002, 13 (07) : 1158 - 1160
  • [6] Randomized comparison of COPP/ABVD vs. dose- and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease.
    Gerhartz, HH
    Schwenke, H
    Bazarbashi, S
    Thiel, E
    Blau, W
    Huhn, D
    Heimpel, H
    Brown, P
    Schliemok, G
    Illiger, HJ
    Walther, J
    Wilmanns, W
    Charisse, G
    Farber, L
    Haus, U
    BLOOD, 1997, 90 (10) : 1731 - 1731
  • [7] Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
    Pavlovsky, Astrid
    Altuve, Juan Ignacio Garcia
    Cerutti, Amalia
    Fiad, Lorena
    Kurgansky, Nicolas
    Warley, Fernando
    Aranguren, Florencia Negri
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S250 - S256
  • [8] Reduced Versus Full Doses of Irradiation After 3 Cycles of Combined Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in Early Stage Hodgkin Lymphomas Results of a Randomized Trial
    Arakelyan, Nina
    Jais, Jean-Philippe
    Delwail, Vincent
    Briere, Josette
    Moles-Moreau, Marie-Pierre
    Senecal, Delphine
    Berthou, Christian
    Desablens, Bernard
    Colonna, Pierre
    Andrieu, Jean-Marie
    CANCER, 2010, 116 (17) : 4054 - 4062
  • [9] ABVD vs. radiotherapy in early stage Hodgkin's lymphoma A critical look at the NCIC HD.6 trial
    Wenz, F.
    Abo-Madyan, Y.
    Welzel, G.
    Giordano, F. A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 649 - 652
  • [10] IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL
    Behringer, K.
    Goergen, H.
    Borchmann, P.
    Diehl, V.
    Fuchs, M.
    Lohri, A.
    Hitz, F.
    Zijlstra, J. M.
    Greil, R.
    Markova, J.
    Topp, M. S.
    Soekler, M.
    Mathas, S.
    Meissner, J.
    von Tresckow, B.
    Boell, B.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 497 - 497
12345